US · DXCM
DexCom, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- San Diego, CA 92121
- Website
- dexcom.com
Price · as of 2025-12-31
$61.35
Market cap 28.64B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $84.41 | +37.59% |
| Intrinsic Value(DCF) | $68.93 | +12.36% |
| Graham-Dodd Method(GD) | $17.69 | -71.16% |
| Graham Formula(GF) | $49.41 | -19.47% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $2.56 | $32.93 | $323.56 | $0.00 | $0.00 |
| 2012 | $3.99 | $29.60 | $18.66 | $0.00 | $0.00 |
| 2013 | $11.85 | $38.48 | $84.41 | $0.00 | $0.00 |
| 2014 | $15.01 | $37.34 | $243.29 | $0.08 | $0.00 |
| 2015 | $16.29 | $37.42 | $549.76 | $0.00 | $0.00 |
| 2016 | $19.58 | $37.67 | $452.05 | $0.00 | $0.00 |
| 2017 | $15.03 | $34.32 | $196.90 | $0.45 | $0.00 |
| 2018 | $35.81 | $45.23 | $271.20 | $0.03 | $0.00 |
| 2019 | $71.64 | $61.48 | $441.83 | $3.76 | $13.67 |
| 2020 | $89.43 | $74.66 | $488.50 | $11.32 | $48.89 |
| 2021 | $97.57 | $106.19 | $421.00 | $8.01 | $19.04 |
| 2022 | $107.77 | $99.20 | $267.09 | $9.79 | $22.88 |
| 2023 | $135.25 | $121.39 | $162.79 | $12.31 | $44.15 |
| 2024 | $77.84 | $64.10 | $67.88 | $12.26 | $27.11 |
| 2025 | $73.78 | $84.41 | $68.15 | $17.69 | $49.41 |
AI valuation
Our deep-learning model estimates DexCom, Inc.'s (DXCM) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $84.41
- Current price
- $61.35
- AI upside
- +37.59%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$68.93
+12.36% upside
Graham-Dodd
$17.69
-71.16% upside
Graham Formula
$49.41
-19.47% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| DXCM | DexCom, Inc. | $61.35 | 28.64B | +38% | +12% | -71% | -19% | 34.42 | 10.48 | 6.18 | 24.22 | 72.96 | 10.86 | 60.10% | 19.56% | 17.94% | 34.50% | 32.99% | 13.04% | 0.51 | — | 1.88 | 1.53 | 0.41 | 4718.00% | 1560.00% | 7079.00% | 3.74% | 0.67 | 50.72% | 0.00% | 0.00% | 6.98% | 30.91 | 26.16 | 6.04 | 6.91 |
| BIIB | Biogen Inc. | $191.82 | 28.15B | +13% | -50% | -35% | -56% | 21.34 | 1.51 | 2.81 | 9.91 | — | 10.66 | 70.47% | 19.14% | 13.18% | 7.39% | 8.18% | 4.50% | 0.38 | 7.63 | 2.68 | 1.70 | 1.27 | -2109.00% | 139.00% | -1848.00% | 7.43% | 0.66 | 9.68% | 0.00% | 0.00% | 1.14% | 16.36 | 14.98 | 3.13 | 3.23 |
| LH | Labcorp Holdings Inc. | $289.12 | 23.97B | -28% | -60% | -89% | -45% | 27.16 | 2.77 | 1.71 | 15.16 | 148.18 | -13.50 | 26.75% | 10.87% | 6.28% | 10.53% | 8.26% | 4.77% | 0.84 | 6.77 | 1.42 | 0.99 | 3.31 | 1833.00% | 725.00% | 1005.00% | 5.06% | 0.58 | 8.29% | 1.01% | 27.40% | 2.90% | 20.12 | 25.30 | 2.19 | 3.23 |
| PHG | Koninklijke Philips N.V. | $32.00 | 30.68B | +25% | -54% | -95% | -76% | 28.63 | 2.34 | 1.44 | 11.71 | — | -29.02 | 45.18% | 7.98% | 5.02% | 7.80% | 6.50% | 3.20% | 0.74 | 4.28 | 1.32 | 0.84 | 2.00 | -22400.00% | -104.00% | -3406.00% | 3.49% | 0.15 | 5.36% | 1.28% | 36.60% | 1.28% | 21.71 | 34.62 | 1.73 | 2.09 |
| PODD | Insulet Corporation | $246.61 | 17.36B | -11% | +250% | -84% | -46% | 69.88 | 11.40 | 6.38 | 29.99 | — | 12.82 | 71.63% | 17.50% | 9.12% | 18.12% | 19.54% | 7.87% | 0.69 | 5.94 | 2.78 | 1.81 | 0.57 | -3979.00% | 3073.00% | 2367.00% | 2.19% | 0.84 | 21.40% | 0.00% | 0.00% | 1.12% | 37.15 | 46.60 | 6.50 | 8.10 |
| SNN | Smith & Nephew plc | $36.90 | 16.13B | +1% | -68% | — | -68% | 30.99 | 2.43 | 2.20 | 12.51 | — | 10.58 | 69.64% | 11.31% | 7.09% | 7.86% | 6.81% | 4.05% | 0.63 | 3.91 | 2.89 | 1.19 | 2.18 | -2167.00% | 470.00% | 23481.00% | 4.75% | 0.64 | 7.59% | 2.56% | 79.40% | 3.19% | 23.55 | 25.53 | 2.66 | 3.29 |
| STE | STERIS plc | $252.35 | 24.77B | -33% | -62% | -91% | -65% | 38.71 | 3.61 | 4.37 | 19.05 | 61.70 | 36.50 | 44.01% | 15.87% | 11.26% | 9.55% | 7.35% | 5.81% | 0.33 | 10.05 | 1.96 | 1.19 | 1.49 | 6273.00% | 624.00% | 2693.00% | 3.26% | 1.12 | 8.59% | 0.92% | 35.70% | 6.61% | 29.86 | 33.26 | 4.74 | 5.33 |
| TEVA | Teva Pharmaceutical Indus… | $33.86 | 38.83B | +22% | -53% | — | -55% | 27.36 | 4.91 | 2.25 | 16.76 | — | -3.27 | 51.79% | 12.50% | 8.17% | 21.35% | 10.30% | 3.54% | 2.20 | 2.35 | 1.04 | 0.54 | 4.40 | -18276.00% | 431.00% | 5327.00% | 2.96% | 0.12 | 5.48% | 0.00% | 0.00% | 2.46% | 24.40 | 45.84 | 3.05 | 0.85 |
| WAT | Waters Corporation | $319.38 | 19.01B | -23% | -58% | -77% | -50% | 28.45 | 7.14 | 5.78 | 18.88 | 6094.04 | 27.58 | 57.77% | 28.22% | 20.30% | 29.28% | 23.09% | 13.34% | 0.55 | 17.59 | — | — | 0.81 | 47.00% | 699.00% | -1288.00% | 2.95% | — | 16.39% | 0.00% | 0.00% | 3.13% | 21.39 | 35.39 | 6.04 | 6.02 |
| WST | West Pharmaceutical Servi… | $254.34 | 18.32B | -20% | -57% | -75% | -62% | 36.79 | 5.72 | 5.91 | 24.59 | 2237.77 | 5.94 | 35.89% | 20.09% | 16.06% | 16.85% | 18.68% | 12.48% | 0.13 | 1029.00 | 3.02 | 2.09 | -0.52 | 164.00% | 626.00% | 6965.00% | 2.58% | 1.15 | 17.68% | 0.34% | 12.40% | 2.15% | 28.82 | 37.94 | 5.79 | 12.97 |
| ZBH | Zimmer Biomet Holdings, I… | $98.44 | 19.51B | +4% | -60% | -82% | -46% | 27.93 | 1.55 | 2.39 | 12.01 | — | -10.06 | 61.62% | 16.55% | 8.57% | 5.60% | 6.12% | 3.17% | 0.59 | 4.65 | 1.98 | 0.89 | 3.12 | -1986.00% | 720.00% | 2887.00% | 7.47% | 0.66 | 7.80% | 0.97% | 27.00% | 3.44% | 19.55 | 18.08 | 3.23 | 1.82 |
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
- CEO
- Jacob Steven Leach
- Employees
- 10.2K
- Beta
- 1.49
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($68.93 ÷ $61.35) − 1 = +12.36% (DCF, example).